Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oritavancin diphosphate to preparation of medicines for preventing and treating infectious bovine rhinotracheitis

A technology for oritavancin phosphate and rhinotracheitis, applied in the field of medicine, can solve problems such as hidden safety hazards, inability to remove viruses, and strong toxicity

Active Publication Date: 2019-04-02
DAIRY CATTLE RES CENT SHANDONG ACADEMY OF AGRI SCI +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Individuals after immunization with inactivated vaccines cannot be differentially diagnosed with naturally infected individuals, so it will bring certain obstacles to the eradication of bovine infectious rhinotracheitis
Traditional attenuated vaccines have the phenomenon of virulence returning to strength, and there are certain safety hazards
The most important thing is that bovine infectious rhinotracheitis virus is an intracellular proliferating virus, and inactivated vaccines cannot remove the virus in the body, but can only prevent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oritavancin diphosphate to preparation of medicines for preventing and treating infectious bovine rhinotracheitis
  • Application of oritavancin diphosphate to preparation of medicines for preventing and treating infectious bovine rhinotracheitis
  • Application of oritavancin diphosphate to preparation of medicines for preventing and treating infectious bovine rhinotracheitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 bovine infectious rhinotracheitis virus TCID 50 Determination of

[0041] MDBK cells (preserved by Dairy Cow Research Center, Shandong Academy of Agricultural Sciences) were digested and mixed with 1 × 10 per well. 5 Cells / mL were seeded into 96-well cell culture plates, placed in 37°C, 5% CO 2 After being cultured into a single layer of cells in the cell incubator, the cell growth solution in the well was discarded, and the virus dilution solution of bovine infectious rhinotracheitis virus (preserved by the Dairy Cow Research Center, Shandong Academy of Agricultural Sciences) was serially diluted 10 times (dilutions were respectively for 10 -1 ~10 -10 ) inoculated in a 96-well plate full of monolayer cells, 100 μL per well, placed in 37°C, 5% CO 2 Continue culturing in a special incubator, observe the CPE (cytopathic effect) of the cells day by day, and record the number of cytopathic wells in detail. At the same time, a normal cell control group and a...

Embodiment 2

[0052] Example 2 Toxicity test of oritavancin phosphate on MDBK cells:

[0053] MDBK cells are susceptible cells to bovine infectious rhinotracheitis virus. Therefore, the cytotoxicity of oritavancin phosphate to MDBK cells was first detected, and the specific experimental steps were as follows:

[0054] (1) Inoculate 100 μL cells (MDBK 5000 cells / well) in a 96-well plate.

[0055] (2) After culturing for about 12 hours, the next step of drug addition analysis was carried out. The medium was discarded, and 100 μL of 2% FBS DMEM containing different drug concentrations (starting at 50 μM, serially diluted twice to obtain 9 concentrations of 25 μM, 12.5 μM, 6.25 μM, and 3.125 μM) was added to each well. Do 3 parallels for each concentration. At the same time, control wells: add 100 μL of 2% FBS DMEM medium containing 0.9% DMSO. Zero well: no cells are plated.

[0056] (3) At 37°C, 5% CO 2 After culturing for 48 h under the condition, the medium in the well was discarded....

Embodiment 3

[0061] Example 3 Inhibitory experiment of oritavancin phosphate on bovine infectious rhinotracheitis virus:

[0062] (1) Inoculate 1×10 in each well of a 96-well plate 4 MDBK cells, 37°C, 5% CO 2 Cultivate overnight in an incubator;

[0063] (2) Discard the medium and add 100 μL of 100 TCID to each well 50 Bovine infectious rhinotracheitis virus virus dilution (use 2% FBS DMEM cells to overgrow and add virus dilution, according to 50 μ M initial concentration, two-fold concentration gradient dilution adds medicine, 5% CO 2 Cultivated in an incubator;

[0064] (3) After 48 hours, operate according to the instructions of the CCK-8 kit, and measure the OD value at 450 nm with a microplate reader.

[0065](4) analysis data, virus inhibition rate (%)=(drug treatment group D450nm value-virus control group D450nm value) / (normal cell control group D450nm value-virus control group D450nm value) * 100%, get with GraphPad Prism5 software The half effective concentration of the com...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Ec50aaaaaaaaaa
Ec50aaaaaaaaaa
Login to View More

Abstract

The invention provides an application of oritavancin diphosphate to preparation of medicines for preventing and treating infectious bovine rhinotracheitis. On a MDBK cell model of in-vitro experiment,the oritavancin diphosphate can restrain and kill infectious bovine rhinotracheitis viruses, can effectively restrain invasion and duplication of the infectious bovine rhinotracheitis viruses, is small in cytotoxicity, can be used as a new medicine for resisting the infectious bovine rhinotracheitis viruses, establishes foundation for prevention and control of infectious bovine rhinotracheitis diseases and research and development of medicines, also establishes experiment foundation and provides new view for development of high-efficiency specific infectious bovine rhinotracheitis virus resisting medicines.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of oritavancin phosphate in the preparation of medicines for preventing and treating bovine infectious rhinotracheitis. Background technique [0002] The information disclosed in this background section is only intended to increase the understanding of the general background of the present invention, and is not necessarily taken as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to those skilled in the art. [0003] Infectious bovine rhinotracheitis (IBR) is an acute, febrile, contact infectious disease caused by infectious bovine rhinotracheitis virus (IBRV), characterized by high fever, dyspnea, Runny nose, inflammation of the upper respiratory tract, trachea, and mucous membranes are characteristic. In the early 1950s, infectious cattle disease with symptoms of rhinotracheitis appeared for the first time in some ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/14A61P31/22
CPCA61K38/14A61P31/22
Inventor 楚会萌程凯慧杨宏军任亚初解晓莉张亮于志君
Owner DAIRY CATTLE RES CENT SHANDONG ACADEMY OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com